AMLODIPINE/VALSARTAN NOVARTIS10/320 amlodipine 10 mg/valsartan 320 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

amlodipine/valsartan novartis10/320 amlodipine 10 mg/valsartan 320 mg film-coated tablet blister pack

novartis pharmaceuticals australia pty ltd - amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg); valsartan, quantity: 320 mg - tablet, film coated - excipient ingredients: crospovidone; colloidal anhydrous silica; sodium starch glycollate; microcrystalline cellulose; magnesium stearate; iron oxide yellow; titanium dioxide; hypromellose; purified talc; macrogol 4000 - amlodipine/valsartan novartis is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

AMLODIPINE/VALSARTAN/HCT NOVARTIS 10/320/25  amlodipine/valsartan/hydrochlorothiazide tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

amlodipine/valsartan/hct novartis 10/320/25 amlodipine/valsartan/hydrochlorothiazide tablet blister pack

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 320 mg; hydrochlorothiazide, quantity: 25 mg; amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg) - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; crospovidone; microcrystalline cellulose; hypromellose; purified talc; iron oxide yellow; macrogol 4000 - amlodipine/valsartan/hct novartis is indicated only as substitution therapy for the treatment of hypertension in patients whose blood pressure is already adequately controlled on the triple combination of amlodipine, valsartan and hydrochlorothiazide taken either as three single component formulations or as dual-component formulation with a single component formulation, all components at the same dose level. treatment should not be initiated with these fixed-dose combinations (see dosage and administration).

EXFORGE HCT 10/320/25 amlodipine/valsartan/hydrochlorothiazide tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

exforge hct 10/320/25 amlodipine/valsartan/hydrochlorothiazide tablet blister pack

novartis pharmaceuticals australia pty ltd - hydrochlorothiazide, quantity: 25 mg; valsartan, quantity: 320 mg; amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg) - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; crospovidone; hypromellose; purified talc; iron oxide yellow; macrogol 4000 - exforge hct is indicated only as substitution therapy for the treatment of hypertension in patients whose blood pressure is already adequately controlled on the triple combination of amlodipine, valsartan and hydrochlorothiazide taken either as three single component formulations or as dual-component formulation with a single component formulation, all components at the same dose level. treatment should not be initiated with these fixed-dose combinations (see dosage and administration).

EXFORGE 10/320 amlodipine (as besilate) and valsartan 10/320mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

exforge 10/320 amlodipine (as besilate) and valsartan 10/320mg film-coated tablet blister pack

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 320 mg; amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate; magnesium stearate; iron oxide yellow; crospovidone; colloidal anhydrous silica; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; macrogol 4000 - exforge is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

AMLODIPINE/VALSARTAN/HCT SANDOZ 10/320/25 amlodipine/valsartan/hydrochlorothiazide tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

amlodipine/valsartan/hct sandoz 10/320/25 amlodipine/valsartan/hydrochlorothiazide tablet blister pack

novartis pharmaceuticals australia pty ltd - hydrochlorothiazide, quantity: 25 mg; valsartan, quantity: 320 mg; amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg) - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; crospovidone; hypromellose; purified talc; iron oxide yellow; macrogol 4000 - amlodipine/valsartan/hct sandoz is indicated only as substitution therapy for the treatment of hypertension in patients whose blood pressure is already adequately controlled on the triple combination of amlodipine, valsartan and hydrochlorothiazide taken either as three single component formulations or as dual-component formulation with a single component formulation, all components at the same dose level. treatment should not be initiated with these fixed-dose combinations (see dosage and administration).

AMLODIPINE/VALSARTAN SANDOZ 10/320 amlodipine (as besilate) and valsartan 10/320mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

amlodipine/valsartan sandoz 10/320 amlodipine (as besilate) and valsartan 10/320mg film-coated tablet blister pack

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 320 mg; amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate; magnesium stearate; iron oxide yellow; crospovidone; colloidal anhydrous silica; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; macrogol 4000 - exforge is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

AMLODIPINE/VALSARTAN/HCT NOVARTIS 10/160/25  amlodipine/valsartan/hydrochlorothiazide tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

amlodipine/valsartan/hct novartis 10/160/25 amlodipine/valsartan/hydrochlorothiazide tablet blister pack

novartis pharmaceuticals australia pty ltd - amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg); hydrochlorothiazide, quantity: 25 mg; valsartan, quantity: 160 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; crospovidone; microcrystalline cellulose; hypromellose; purified talc; iron oxide yellow; macrogol 4000 - amlodipine/valsartan/hct novartis is indicated only as substitution therapy for the treatment of hypertension in patients whose blood pressure is already adequately controlled on the triple combination of amlodipine, valsartan and hydrochlorothiazide taken either as three single component formulations or as dual-component formulation with a single component formulation, all components at the same dose level. treatment should not be initiated with these fixed-dose combinations (see dosage and administration).

AMLODIPINE/VALSARTAN/HCT NOVARTIS 10/160/12.5 amlodipine/valsartan/hydrochlorothiazide tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

amlodipine/valsartan/hct novartis 10/160/12.5 amlodipine/valsartan/hydrochlorothiazide tablet blister pack

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 160 mg; amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg); hydrochlorothiazide, quantity: 12.5 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; crospovidone; magnesium stearate; hypromellose; purified talc; iron oxide red; macrogol 4000; iron oxide yellow; titanium dioxide - amlodipine/valsartan/hct novartis is indicated only as substitution therapy for the treatment of hypertension in patients whose blood pressure is already adequately controlled on the triple combination of amlodipine, valsartan and hydrochlorothiazide taken either as three single component formulations or as dual-component formulation with a single component formulation, all components at the same dose level. treatment should not be initiated with these fixed-dose combinations (see dosage and administration).

EXFORGE HCT 10/160/12.5 amlodipine/valsartan/hydrochlorothiazide tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

exforge hct 10/160/12.5 amlodipine/valsartan/hydrochlorothiazide tablet blister pack

novartis pharmaceuticals australia pty ltd - amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg); valsartan, quantity: 160 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; hypromellose; purified talc; iron oxide red; macrogol 4000; titanium dioxide; iron oxide yellow - exforge hct is indicated only as substitution therapy for the treatment of hypertension in patients whose blood pressure is already adequately controlled on the triple combination of amlodipine, valsartan and hydrochlorothiazide taken either as three single component formulations or as dual-component formulation with a single component formulation, all components at the same dose level. treatment should not be initiated with these fixed-dose combinations (see dosage and administration).

EXFORGE HCT 10/160/25 amlodipine/valsartan/hydrochlorothiazide tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

exforge hct 10/160/25 amlodipine/valsartan/hydrochlorothiazide tablet blister pack

novartis pharmaceuticals australia pty ltd - hydrochlorothiazide, quantity: 25 mg; amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg); valsartan, quantity: 160 mg - tablet, film coated - excipient ingredients: crospovidone; microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; hypromellose; purified talc; iron oxide yellow; macrogol 4000 - exforge hct is indicated only as substitution therapy for the treatment of hypertension in patients whose blood pressure is already adequately controlled on the triple combination of amlodipine, valsartan and hydrochlorothiazide taken either as three single component formulations or as dual-component formulation with a single component formulation, all components at the same dose level. treatment should not be initiated with these fixed-dose combinations (see dosage and administration).